Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.70 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7179898 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL665803 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL1358020 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL3790808 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL8177155 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL1358207 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL4748375 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL6461117 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL22322881 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 | |
| SCHEMBL6467454 | 1.00 | GPR84 (0.70) | GPR84SLC22A6KDM4CKDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227290-B2 | Glycosphingolipids for use in modulating immune responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2811831-B1 | GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES | UNIV CALIFORNIA (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9309276-B2 | Synthetic lipid A derivative | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140377291-A1 | GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2014-12-25 | — | — | US | disclosed |
| EP-2811831-A1 | GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140011987-A1 | Synthetic Lipid A Derivative | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563523-B2 | Synthetic lipid A derivative | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2013119857-A1 | GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20110280893-A9 | SYNTHETIC LIPID A DERIVATIVE | UNIVERSITY OF GEORGIA RESEACH FOUNDATION, INC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100221269-A1 | SYNTHETIC LIPID A DERIVATIVE | UNIVERSITY OF GEORGIA RESEACH FOUNDATION, INC (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2009035528-A2 | SYNTHETIC LIPID A DERIVATIVE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011987-A1 | Synthetic Lipid A Derivative | DDOST, STT3A, UGCG | GPR84 925/4885SLC22A6 1255/4885KDM4C 2585/4885 |
| US-20140377291-A1 | GLYCOSPHINGOLIPIDS FOR USE IN MODULATING IMMUNE RESPONSES | SGMS1, SGMS2, UGCG | GPR84 813/4885SLC22A6 2055/4885KDM4C 2681/4885 |
| US-20110280893-A9 | SYNTHETIC LIPID A DERIVATIVE | DDOST, STT3A, UGCG | GPR84 925/4885SLC22A6 1255/4885KDM4C 2585/4885 |
| US-20100221269-A1 | SYNTHETIC LIPID A DERIVATIVE | DDOST, STT3A, UGCG | GPR84 925/4885SLC22A6 1255/4885KDM4C 2585/4885 |
| US-10227290-B2 | Glycosphingolipids for use in modulating immune responses | SGMS1, SGMS2, UGCG | GPR84 813/4885SLC22A6 2055/4885KDM4C 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.